Sunshine Biopharma (SBFM) Research & Development (2011 - 2026)
Sunshine Biopharma (SBFM) posted Research & Development of $31724.0 for Q1 2026, down 56.84% on a QoQ basis from $73501.0 in Q4 2025, and down 85.26% year-over-year from $215277.0 in Q1 2025.
Sunshine Biopharma (SBFM) Research & Development (2011 - 2026) Analysis & Trends
Sunshine Biopharma's Research & Development history runs 14 years deep, the most recent figure standing at $31724.0 for Q1 2026.
- Quarterly Research & Development fell 85.26% year-over-year to $31724.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $420755.0 (down 54.62% YoY) and the FY2025 annual result came in at $604308.0, down 35.29% from the prior year.
- Research & Development was $31724.0 for Q1 2026 at Sunshine Biopharma, down from $73501.0 in the prior quarter.
- Across five years, Research & Development topped out at $816328.0 in Q4 2023 and bottomed at $31724.0 in Q1 2026.
- A 5-year average of $249271.9 and a median of $215277.0 in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development soared 1854.67% — and 2026, when it sank 85.26%.
- Sunshine Biopharma's Research & Development stood at $41763.0 in 2022, then surged by 1854.67% to $816328.0 in 2023, then plunged by 81.71% to $149272.0 in 2024, then tumbled by 50.76% to $73501.0 in 2025, then sank by 56.84% to $31724.0 in 2026.
- Business Quant data shows SBFM's Research & Development at $31724.0 in Q1 2026, $73501.0 in Q4 2025, and $119298.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 138.20 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Sunshine Biopharma | 750,608.81 | -6.16 Mn | 2.18 Mn | 31,724.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31,724.00 |
| Dec 31, 2025 | 73,501.00 |
| Sep 30, 2025 | 119,298.00 |
| Jun 30, 2025 | 196,232.00 |
| Mar 31, 2025 | 215,277.00 |
| Dec 31, 2024 | 149,272.00 |
| Sep 30, 2024 | 126,362.00 |
| Jun 30, 2024 | 436,235.00 |
| Mar 31, 2024 | 222,033.00 |
| Dec 31, 2023 | 816,328.00 |
| Sep 30, 2023 | 238,012.00 |
| Jun 30, 2023 | 368,565.00 |
| Mar 31, 2023 | 432,925.00 |
| Dec 31, 2022 | 41,763.00 |
| Sep 30, 2022 | 362,500.00 |
| Jun 30, 2022 | 45,943.00 |
| Mar 31, 2022 | 361,652.00 |
| Dec 31, 2021 | 91,198.00 |
| Sep 30, 2021 | 222,465.00 |
| Jun 30, 2021 | 191,760.00 |